View Document Preview and Link Document Date: 2013-02-19 15:45:37 Open Document File Size: 1,93 MB Share Result on Facebook
City Kumar / Dimopoulos / Calgary / / Company New England Journal / Meducom Health Inc. / International Myeloma Working Group / Eastern Cooperative Oncology Group / Celgene Inc. / / Event FDA Phase / / Facility University of Calgary / Tom Baker Cancer Centre / / IndustryTerm Cancer Treat / imaging / treatment of residual disease / / MedicalCondition refractory disease / Leukemia / minimal residual disease / Cancer / multiple myeloma / residual disease / disease / low-grade lymphomas / myelodysplastic syndrome / follicular lymphoma / progressive disease / neutropenia / tumour / thrombocytopenia / plasma cell leukemia / large-cell lymphomas / bone disease / soft-tissue plasmacytomas / multiple myeloma today / plasmacytomas / Hypercalcemia / residual clonal disease / relapse disease / plasma cell dyscrasias / myeloma Multiple myeloma / acute myeloid leukemia / multiple myeloma patients / / MedicalTreatment salvage therapy / AID / chemotherapy / / OperatingSystem NEMESIS / / Organization Tom Baker Cancer Centre / Biologics and Genetic Therapies Directorate / University of Calgary / Southern Alberta Cancer Research Institute / Health Canada’s Therapeutic Products Directorate / / Person Arch Int Med / Nizar Bahlis / / Position Hb / Walker / MP / Associate Professor / Professor of Medicine / / Product cisplatin / etoposide / dexamethasone / cyclophosphamide / prednisone / TNT / HOVON-65/ GMMG / MM-015 / / ProgrammingLanguage D / R / C / / ProvinceOrState Alberta / New Jersey / Saskatchewan / Massachusetts / / PublishedMedium the New England Journal of Medicine / / Region New England / Southern Alberta / / TVStation Kyle / / Technology genomics / artificial intelligence / magnetic resonance imaging / chemotherapy / transplantation / recombination / MRI / / SocialTag 
REVIEW Continuous therapy with lenalidomide in multiple myeloma by Nizar Bahlis, MD